Mitochondrial dysfunction in fibrotic diseases.

Area of Science:

• Cell Biology
• Pathology
• Organelle Biology

Background:

• Fibrosis is a common feature in end-stage organ diseases, but its underlying mechanisms are not fully understood.
• Mitochondrial dysfunction is increasingly implicated in the development and progression of fibrotic conditions.
• Organs with high oxygen consumption, such as the heart, liver, kidney, and lung, are particularly susceptible to mitochondrial dysfunction and fibrosis.

Purpose of the Study:

• To review and summarize the emerging mechanisms linking mitochondrial dysfunction to fibrosis across various organs and tissues.
• To highlight key mitochondrial alterations involved in fibrotic processes.
• To explore the role of mitophagy and mitochondrial transfer in fibrosis.

Main Methods:

• Literature review of studies investigating mitochondrial dysfunction in fibrotic diseases.
• Analysis of mechanisms including mitochondrial morphology, membrane potential, DNA damage, and reactive oxygen species (ROS) production.
• Examination of the roles of mitophagy and mitochondrial transfer in fibrotic pathogenesis.

Main Results:

• Mitochondrial dysfunction, evidenced by morphological changes, altered membrane potential, structural damage, and increased reactive oxidative species (ROS) production, is a significant factor in fibrosis.
• Impaired mitophagy and abnormal mitochondrial transfer also contribute to the fibrotic process in affected tissues.
• These findings underscore the central role of mitochondria in the pathogenesis of diverse fibrotic diseases.

Conclusions:

• Growing knowledge of mitochondrial structure, function, and origin provides a basis for novel diagnostic and therapeutic strategies.
• Targeting mitochondrial dysfunction offers a promising approach for treating a wide range of fibrotic diseases.
• Further research into mitochondrial mechanisms could revolutionize the management of organ fibrosis.